Shares in Actelion Ltd. rose 15 percent during trading Monday on news that selexipag, its first-in-class selective oral prostacyclin IP receptor agonist, met the primary endpoint of a phase III outcomes trial in 1,156 patients with pulmonary arterial hypertension (PAH).